Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 67.2%

Neg 0% Neu 0% Pos 67.2%

Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.

Comments

No comments yet. Be the first!